Literature DB >> 28127177

Prognostic Benefit of Surgical Management of Renal Cell Carcinoma Invading the Inferior Vena Cava.

Aikaterini Mastoraki1, Sotiria Mastoraki1, Maria Tsikala-Vafea1, Ioannis S Papanikolaou1, Andreas Lazaris1, Vassilios Smyrniotis1, Nikolaos Arkadopoulos1.   

Abstract

Renal cell carcinoma (RCC) accounts for approximately 3 % of adult malignancies and 90-95 % of neoplasms arising from the kidney. One of the unique features of RCC is the tumor thrombus formation that migrates into the venous system including renal vein (RV) and inferior vena cava (IVC). Only 10 % of patients with RCC present with the classic triad of flank pain, hematuria and defined mass, while 25-30 % of affected patients are asymptomatic. Signs of para-neoplastic syndrome such as hypercalcemia, hypertension, anemia, cachexia and increased erythrocyte sedimentation rate (ESR) are often apparent. Extension of tumor thrombus into the venous system is depicted by radiological examinations, such as contrast enhanced Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and vena cavography. The level of the thrombus is mostly determined according to the Mayo classification. Despite recent research on the therapeutic strategies against advanced RCC, surgical resection appears the only potentially curative approach. Aggressive surgical management including nephrectomy with thrombectomy is currently the standard therapeutic approach for RCC patients with tumor thrombus extending to the RV or the IVC. Pre-surgical down-staging with the use of molecular targeted therapy has also been proposed. Alternative therapies, such as radio- and chemotherapy proved insufficient. The aim of this review is to evaluate the results of surgical treatment for RCC invading IVC with special reference to the extent of its histological spread. Review of recent world literature was accomplished to provide an update on the current concepts of surgical management of the disease.

Entities:  

Keywords:  Diagnostic approach; Inferior vena cava infiltration; Renal cell carcinoma; Surgical strategies

Year:  2016        PMID: 28127177      PMCID: PMC5236014          DOI: 10.1007/s13193-016-0528-y

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  34 in total

1.  Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better?

Authors:  Badrinath R Konety; Veerasathpurush Allareddy; Sanjukta Modak; Brian Smith
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

2.  Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus.

Authors:  J C Nesbitt; E R Soltero; C P Dinney; G L Walsh; D S Schrump; D A Swanson; L L Pisters; K D Willis; J B Putnam
Journal:  Ann Thorac Surg       Date:  1997-06       Impact factor: 4.330

3.  Resection of large inferior vena caval thrombi from renal cell carcinoma with the use of circulatory arrest.

Authors:  J E Montie; C L Jackson; D M Cosgrove; S B Streem; A C Novick; J E Pontes
Journal:  J Urol       Date:  1988-01       Impact factor: 7.450

4.  The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.

Authors:  Nicholas G Cost; Scott E Delacroix; Joshua P Sleeper; Paul J Smith; Ramy F Youssef; Brian F Chapin; Jose A Karam; Stephen Culp; E Jason Abel; James Brugarolas; Ganesh V Raj; Arthur I Sagalowsky; Christopher G Wood; Vitaly Margulis
Journal:  Eur Urol       Date:  2011-02-23       Impact factor: 20.096

5.  Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: single-center experience.

Authors:  Tsunenori Kondo; Eri Ikezawa; Toshio Takagi; Hirohito Kobayashi; Yasunobu Hashimoto; Junpei Iizuka; Kenji Omae; Kazuhiko Yoshida; Kazunari Tanabe
Journal:  Int J Urol       Date:  2013-02-20       Impact factor: 3.369

Review 6.  The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma.

Authors:  Leonardo D Borregales; Mehrad Adibi; Arun Z Thomas; Christopher G Wood; Jose A Karam
Journal:  Ther Adv Urol       Date:  2015-11-20

7.  IVC Thrombectomy in Renal Cell Carcinoma-Analysis of Out Come Data of 100 Patients and Review of Literature.

Authors:  Jagdeesh Kulkarni; Yogesh Jadhav; Rohan S Valsangkar
Journal:  Indian J Surg Oncol       Date:  2011-12-20

Review 8.  Unusual forms of pulmonary embolism.

Authors:  M B King; K R Harmon
Journal:  Clin Chest Med       Date:  1994-09       Impact factor: 2.878

9.  Presurgical downstaging of vena caval tumor thrombus in advanced clear cell renal cell carcinoma using temsirolimus.

Authors:  Futoshi Sano; Kazuhide Makiyama; Tomoyuki Tatenuma; Ryoko Sakata; Hiroyuki Yamanaka; Syusei Fusayasu; Takashi Nakayama; Noboru Nakaigawa; Masahiro Yao; Yoshinobu Kubota
Journal:  Int J Urol       Date:  2012-11-27       Impact factor: 3.369

10.  Successful management of pulmonary and inferior vena cava tumor embolism from renal cell carcinoma.

Authors:  Hunbo Shim; Wook Sung Kim; Young-Wook Kim; Shin-Seok Yang; Duk-Kyung Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-10-09
View more
  3 in total

1.  Tailoring the Best Technique in the Surgical Management of IVC Thrombosis.

Authors:  Fabrizio Dal Moro
Journal:  Indian J Surg Oncol       Date:  2017-08-25

2.  Accompanying role of hepato-biliary-pancreas surgeon in urological surgery.

Authors:  Atsushi Nanashima; Masahide Hiyoshi; Naoya Imamura; Kouichi Yano; Takeomi Hamada; Takashi Wada; Yoshiro Fujii; Fumiaki Kawano; Takuto Ikeda; Shinsuke Takeno; Eisaku Nakamura; Kunihide Nakamura; Shoichiro Mukai; Toshio Kamimura; Toshiyuki Kamoto
Journal:  Int J Surg Case Rep       Date:  2017-10-27

3.  A Predictive Model for Tumor Invasion of the Inferior Vena Cava Wall Using Multimodal Imaging in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus.

Authors:  Zhuo Liu; Liwei Li; Peng Hong; Guodong Zhu; Shiying Tang; Xun Zhao; Qiming Zhang; Guoliang Wang; Wei He; Hua Zhang; Heng Xue; Ligang Cui; Huiyu Ge; Jie Jiang; Shudong Zhang; Fangting Cao; Jing Yan; Fengrong Ma; Cheng Liu; Lulin Ma; Shumin Wang
Journal:  Biomed Res Int       Date:  2020-10-06       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.